Skip to main content
Top
Published in: Inflammation 2/2019

01-04-2019 | Idiopathic Pulmonary Fibrosis | ORIGINAL ARTICLE

Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP

Authors: David Bennett, Martina Salvini, Annalisa Fui, Giuseppe Cillis, Paolo Cameli, Maria Antonietta Mazzei, Antonella Fossi, Rosa Metella Refini, Paola Rottoli

Published in: Inflammation | Issue 2/2019

Login to get access

Abstract

Idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) are the most frequent idiopathic interstitial pneumonias. The aim of this study was to evaluate concentrations of calgranulin B and Krebs von den Lungen 6 (KL-6) in bronchoalveolar lavage (BAL) fluid of patients with IPF and idiopathic NSIP (i-NSIP) with fibrotic pattern. Thirty patients with IPF (68.73 ± 8.63 years), 30 with i-NSIP (68.33 ± 7.45 years), and healthy controls were included in the study. Calgranulin B and KL-6 both proved to be significantly higher in BAL of IPF and i-NSIP patients than in healthy controls (p < 0.05). Calgranulin B showed several significant correlations with functional parameters (oxygen demand at rest, 6-min walking test (6MWT), and PFTs); KL-6 was correlated with oxygen demand at rest and during 6MWT. Patients with higher concentrations of both biomarkers (> 75th percentile) had more advanced disease with lower values of FEV1%, FVC%, RV%, TLC%, DLCO% of predicted, distance walked in 6MWT, and BAL neutrophil percentage. Calgranulin B and KL-6 in BAL proved to be reliable biomarkers of IPF and i-NSIP and to have prognostic meaning, discriminating severe and advanced patients. The combination of the two biomarkers can facilitate the stratification of severity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Travis, W.D., U. Costabel, D.M. Hansell, T.E. King Jr., D.A. Lynch, A.G. Nicholson, C.J. Ryerson, J.H. Ryu, M. Selman, A.U. Wells, J. Behr, D. Bouros, K.K. Brown, T.V. Colby, H.R. Collard, C.R. Cordeiro, V. Cottin, B. Crestani, M. Drent, R.F. Dudden, J. Egan, K. Flaherty, C. Hogaboam, Y. Inoue, T. Johkoh, D.S. Kim, M. Kitaichi, J. Loyd, F.J. Martinez, J. Myers, S. Protzko, G. Raghu, L. Richeldi, N. Sverzellati, J. Swigris, D. Valeyre, and ATS/ERS Committee on Idiopathic Interstitial Pneumonias. 2013. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine 188 (6): 733–748.CrossRefPubMedPubMedCentral Travis, W.D., U. Costabel, D.M. Hansell, T.E. King Jr., D.A. Lynch, A.G. Nicholson, C.J. Ryerson, J.H. Ryu, M. Selman, A.U. Wells, J. Behr, D. Bouros, K.K. Brown, T.V. Colby, H.R. Collard, C.R. Cordeiro, V. Cottin, B. Crestani, M. Drent, R.F. Dudden, J. Egan, K. Flaherty, C. Hogaboam, Y. Inoue, T. Johkoh, D.S. Kim, M. Kitaichi, J. Loyd, F.J. Martinez, J. Myers, S. Protzko, G. Raghu, L. Richeldi, N. Sverzellati, J. Swigris, D. Valeyre, and ATS/ERS Committee on Idiopathic Interstitial Pneumonias. 2013. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine 188 (6): 733–748.CrossRefPubMedPubMedCentral
2.
go back to reference Raghu, G., H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, J.A. Lasky, D.A. Lynch, J.H. Ryu, J.J. Swigris, A.U. Wells, J. Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina, D.M. Hansell, T. Johkoh, D.S. Kim, T.E. King Jr., Y. Kondoh, J. Myers, N.L. Müller, A.G. Nicholson, L. Richeldi, M. Selman, R.F. Dudden, B.S. Griss, S.L. Protzko, H.J. Schünemann, and ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183 (6): 788–824.CrossRefPubMedPubMedCentral Raghu, G., H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, J.A. Lasky, D.A. Lynch, J.H. Ryu, J.J. Swigris, A.U. Wells, J. Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina, D.M. Hansell, T. Johkoh, D.S. Kim, T.E. King Jr., Y. Kondoh, J. Myers, N.L. Müller, A.G. Nicholson, L. Richeldi, M. Selman, R.F. Dudden, B.S. Griss, S.L. Protzko, H.J. Schünemann, and ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183 (6): 788–824.CrossRefPubMedPubMedCentral
3.
go back to reference Katzenstein, A.L., and R.F. Fiorelli. 1994. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. The American Journal of Surgical Pathology 18: 136–147.CrossRefPubMed Katzenstein, A.L., and R.F. Fiorelli. 1994. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. The American Journal of Surgical Pathology 18: 136–147.CrossRefPubMed
4.
go back to reference Tzouvelekis, A., J. Herazo-Maya, K. Sakamoto, and D. Bouros. 2016. Biomarkers in the evaluation and management of idiopathic pulmonary fibrosis. Current Topics in Medicinal Chemistry 16 (14): 1587–1598.CrossRefPubMed Tzouvelekis, A., J. Herazo-Maya, K. Sakamoto, and D. Bouros. 2016. Biomarkers in the evaluation and management of idiopathic pulmonary fibrosis. Current Topics in Medicinal Chemistry 16 (14): 1587–1598.CrossRefPubMed
5.
go back to reference Yokoyama, A., K. Kondo, M. Nakajima, T. Matsushima, T. Takahashi, M. Nishimura, M. Bando, Y. Sugiyama, Y. Totani, T. Ishizaki, H. Ichiyasu, M. Suga, H. Hamada, and N. Kohno. 2006. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11 (2): 164–168.CrossRefPubMed Yokoyama, A., K. Kondo, M. Nakajima, T. Matsushima, T. Takahashi, M. Nishimura, M. Bando, Y. Sugiyama, Y. Totani, T. Ishizaki, H. Ichiyasu, M. Suga, H. Hamada, and N. Kohno. 2006. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11 (2): 164–168.CrossRefPubMed
6.
go back to reference Sakamoto, K., H. Taniguchi, Y. Kondoh, T. Johkoh, H. Sumikawa, T. Kimura, O. Nishiyama, K. Kato, K. Kataoka, K. Ono, M. Kitaichi, and Y. Hasegawa. 2010. Serum KL-6 in fibrotic NSIP: correlations with physiologic and radiologic parameters. Respiratory Medicine 104 (1): 127–133.CrossRefPubMed Sakamoto, K., H. Taniguchi, Y. Kondoh, T. Johkoh, H. Sumikawa, T. Kimura, O. Nishiyama, K. Kato, K. Kataoka, K. Ono, M. Kitaichi, and Y. Hasegawa. 2010. Serum KL-6 in fibrotic NSIP: correlations with physiologic and radiologic parameters. Respiratory Medicine 104 (1): 127–133.CrossRefPubMed
7.
go back to reference Bonella, F., X. Long, S. Ohshimo, Y. Horimasu, M. Griese, J. Guzman, N. Kohno, and U. Costabel. 2016. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases 11: 48.CrossRefPubMedPubMedCentral Bonella, F., X. Long, S. Ohshimo, Y. Horimasu, M. Griese, J. Guzman, N. Kohno, and U. Costabel. 2016. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases 11: 48.CrossRefPubMedPubMedCentral
8.
go back to reference Bonella, F., A. Volpe, P. Caramaschi, C. Nava, P. Ferrari, K. Schenk, S. Ohshimo, U. Costabel, and M. Ferrari. 2011. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 28 (1): 27–33.PubMed Bonella, F., A. Volpe, P. Caramaschi, C. Nava, P. Ferrari, K. Schenk, S. Ohshimo, U. Costabel, and M. Ferrari. 2011. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 28 (1): 27–33.PubMed
9.
go back to reference Wakamatsu, K., N. Nagata, H. Kumazoe, K. Oda, H. Ishimoto, M. Yoshimi, S. Takata, M. Hamada, Y. Koreeda, K. Takakura, M. Ishizu, M. Hara, S. Ise, M. Izumi, T. Akasaki, S. Maki, M. Kawabata, H. Mukae, and M. Kawasaki. 2017. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respiratory Investigation 55 (1): 16–23.CrossRefPubMed Wakamatsu, K., N. Nagata, H. Kumazoe, K. Oda, H. Ishimoto, M. Yoshimi, S. Takata, M. Hamada, Y. Koreeda, K. Takakura, M. Ishizu, M. Hara, S. Ise, M. Izumi, T. Akasaki, S. Maki, M. Kawabata, H. Mukae, and M. Kawasaki. 2017. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respiratory Investigation 55 (1): 16–23.CrossRefPubMed
10.
go back to reference Ohshimo, S., N. Ishikawa, Y. Horimasu, N. Hattori, N. Hirohashi, K. Tanigawa, N. Kohno, F. Bonella, J. Guzman, and U. Costabel. 2014. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Medicine 108 (7): 1031–1039.CrossRefPubMed Ohshimo, S., N. Ishikawa, Y. Horimasu, N. Hattori, N. Hirohashi, K. Tanigawa, N. Kohno, F. Bonella, J. Guzman, and U. Costabel. 2014. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Medicine 108 (7): 1031–1039.CrossRefPubMed
11.
go back to reference Zhu, C., Y.B. Zhao, L.F. Kong, Z.H. Li, and J. Kang. 2016. The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases. Zhonghua Jie He He Hu Xi Za Zhi 39 (2): 93–97.PubMed Zhu, C., Y.B. Zhao, L.F. Kong, Z.H. Li, and J. Kang. 2016. The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases. Zhonghua Jie He He Hu Xi Za Zhi 39 (2): 93–97.PubMed
12.
go back to reference Bargagli, E., C. Olivieri, A. Prasse, N. Bianchi, B. Magi, R. Cianti, L. Bini, and P. Rottoli. 2008. Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Inflammation 31 (5): 351–354.CrossRefPubMed Bargagli, E., C. Olivieri, A. Prasse, N. Bianchi, B. Magi, R. Cianti, L. Bini, and P. Rottoli. 2008. Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Inflammation 31 (5): 351–354.CrossRefPubMed
13.
go back to reference Bargagli, E., C. Olivieri, M. Cintorino, R.M. Refini, N. Bianchi, A. Prasse, and P. Rottoli. 2011. Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis? Inflammation 34 (2): 85–91.CrossRefPubMed Bargagli, E., C. Olivieri, M. Cintorino, R.M. Refini, N. Bianchi, A. Prasse, and P. Rottoli. 2011. Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis? Inflammation 34 (2): 85–91.CrossRefPubMed
14.
go back to reference Hara, A., N. Sakamoto, Y. Ishimatsu, T. Kakugawa, S. Nakashima, S. Hara, M. Adachi, H. Fujita, H. Mukae, and S. Kohno. 2012. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respiratory Medicine 106 (4): 571–580.CrossRefPubMed Hara, A., N. Sakamoto, Y. Ishimatsu, T. Kakugawa, S. Nakashima, S. Hara, M. Adachi, H. Fujita, H. Mukae, and S. Kohno. 2012. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respiratory Medicine 106 (4): 571–580.CrossRefPubMed
15.
go back to reference Korthagen, N.M., M.M. Nagtegaal, C.H. van Moorsel, K.M. Kazemier, J.M. van den Bosch, and J.C. Grutters. 2010. MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clinical and Experimental Immunology 161 (2): 342–347.PubMedPubMedCentral Korthagen, N.M., M.M. Nagtegaal, C.H. van Moorsel, K.M. Kazemier, J.M. van den Bosch, and J.C. Grutters. 2010. MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clinical and Experimental Immunology 161 (2): 342–347.PubMedPubMedCentral
16.
go back to reference Miller, M.R., R. Crapo, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, P. Enright, C.P. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi, J. Wanger, and ATS/ERS Task Force. 2005. General considerations for lung function testing. The European Respiratory Journal 26 (1): 153–161.CrossRefPubMed Miller, M.R., R. Crapo, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, P. Enright, C.P. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi, J. Wanger, and ATS/ERS Task Force. 2005. General considerations for lung function testing. The European Respiratory Journal 26 (1): 153–161.CrossRefPubMed
17.
go back to reference Holland, A.E., M.A. Spruit, T. Troosters, M.A. Puhan, V. Pepin, D. Saey, M.C. McCormack, B.W. Carlin, F.C. Sciurba, F. Pitta, J. Wanger, N. MacIntyre, D.A. Kaminsky, B.H. Culver, S.M. Revill, N.A. Hernandes, V. Andrianopoulos, C.A. Camillo, K.E. Mitchell, A.L. Lee, C.J. Hill, and S.J. Singh. 2014. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. The European Respiratory Journal 44 (6): 1428–1446.CrossRefPubMed Holland, A.E., M.A. Spruit, T. Troosters, M.A. Puhan, V. Pepin, D. Saey, M.C. McCormack, B.W. Carlin, F.C. Sciurba, F. Pitta, J. Wanger, N. MacIntyre, D.A. Kaminsky, B.H. Culver, S.M. Revill, N.A. Hernandes, V. Andrianopoulos, C.A. Camillo, K.E. Mitchell, A.L. Lee, C.J. Hill, and S.J. Singh. 2014. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. The European Respiratory Journal 44 (6): 1428–1446.CrossRefPubMed
18.
go back to reference Meyer, K.C., G. Raghu, R.P. Baughman, K.K. Brown, U. Costabel, R.M. du Bois, M. Drent, P.L. Haslam, D.S. Kim, S. Nagai, P. Rottoli, C. Saltini, M. Selman, C. Strange, B. Wood, and American Thoracic Society Committee on BAL in interstitial lung disease. 2012. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 185 (9): 1004–1014.CrossRefPubMed Meyer, K.C., G. Raghu, R.P. Baughman, K.K. Brown, U. Costabel, R.M. du Bois, M. Drent, P.L. Haslam, D.S. Kim, S. Nagai, P. Rottoli, C. Saltini, M. Selman, C. Strange, B. Wood, and American Thoracic Society Committee on BAL in interstitial lung disease. 2012. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 185 (9): 1004–1014.CrossRefPubMed
19.
go back to reference Lim, S.Y., A.E. Yuzhalin, A.N. Gordon-Weeks, and R.J. Muschel. 2016. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene 35 (44): 5735–5745.CrossRefPubMedPubMedCentral Lim, S.Y., A.E. Yuzhalin, A.N. Gordon-Weeks, and R.J. Muschel. 2016. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene 35 (44): 5735–5745.CrossRefPubMedPubMedCentral
20.
go back to reference Nunes, H., K. Schubel, D. Piver, E. Magois, S. Feuillet, Y. Uzunhan, Z. Carton, A. Tazi, P. Levy, P.Y. Brillet, A.G. Nicholson, M. Kambouchner, and D. Valeyre. 2015. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. The European Respiratory Journal 45 (3): 746–755.CrossRefPubMed Nunes, H., K. Schubel, D. Piver, E. Magois, S. Feuillet, Y. Uzunhan, Z. Carton, A. Tazi, P. Levy, P.Y. Brillet, A.G. Nicholson, M. Kambouchner, and D. Valeyre. 2015. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. The European Respiratory Journal 45 (3): 746–755.CrossRefPubMed
21.
go back to reference Hamai, K., H. Iwamoto, N. Ishikawa, Y. Horimasu, T. Masuda, S. Miyamoto, T. Nakashima, S. Ohshimo, K. Fujitaka, H. Hamada, N. Hattori, and N. Kohno. 2016. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Disease Markers 2016: 4759040.CrossRefPubMedPubMedCentral Hamai, K., H. Iwamoto, N. Ishikawa, Y. Horimasu, T. Masuda, S. Miyamoto, T. Nakashima, S. Ohshimo, K. Fujitaka, H. Hamada, N. Hattori, and N. Kohno. 2016. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Disease Markers 2016: 4759040.CrossRefPubMedPubMedCentral
Metadata
Title
Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP
Authors
David Bennett
Martina Salvini
Annalisa Fui
Giuseppe Cillis
Paolo Cameli
Maria Antonietta Mazzei
Antonella Fossi
Rosa Metella Refini
Paola Rottoli
Publication date
01-04-2019
Publisher
Springer US
Published in
Inflammation / Issue 2/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-018-00955-2

Other articles of this Issue 2/2019

Inflammation 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.